AI in Healthcare
The latest on artificial intelligence transforming medicine
News stories discovered and organized by an automated pipeline. Covering clinical deployments, research breakthroughs, regulation, and industry developments.
AI Drug Discovery’s Great Divide: Scale, Speed, and What Actually Works
The AI drug discovery market is increasingly split between companies building broad, platform-style systems and those focused on narrower, more experimentally grounded workflows. The debate is no longer whether AI belongs in drug discovery, but which operating model is most likely to produce real-world candidates and returns.
Lilly’s Insilico Pact Turns AI Drug Discovery Into Big-Pharma Procurement
Eli Lilly’s multibillion-dollar collaboration with Insilico Medicine is significant less for its headline size than for what it says about how large drugmakers now buy AI-enabled discovery capacity. The deal suggests AI platforms are no longer being evaluated as speculative innovation projects, but as sourcing channels for future drug candidates.
Eli Lilly’s reported $2 billion Insilico deal raises the stakes for AI drug development
Reuters reports Eli Lilly is set to sign a deal worth up to $2 billion with Insilico Medicine, a major signal that large pharma still sees strategic value in AI-native drug discovery platforms. The significance is less about headline size alone and more about what it says regarding confidence in externalized R&D models, especially when AI partners can offer speed, target selection, and chemistry capabilities in one package.
Zealand Pharma’s Cambridge expansion shows AI-era drug discovery still clusters around talent and infrastructure
Zealand Pharma’s decision to establish a U.S. research hub in Cambridge, Massachusetts underscores that even in an AI-driven discovery era, geography still matters. The move points to a competitive logic centered on talent density, partnerships, and rapid iteration rather than purely digital scale.
AI Agents Are Challenging Drug Discovery’s Step-by-Step Playbook
A new 36Kr report argues that AI agents are beginning to break from traditional sequential problem-solving in drug development, potentially helping teams overcome cognitive blind spots. The bigger story is that biopharma is testing whether agentic systems can do more than automate tasks and instead reshape scientific reasoning itself.
Takeda’s $1.7 Billion Iambic Bet Shows Big Pharma Still Pays for AI-Validated Small-Molecule Platforms
Takeda and Iambic Therapeutics have announced a deal worth up to $1.7 billion to advance small-molecule programs, adding another major validation point for AI-enabled drug discovery. The agreement suggests large pharma remains willing to spend heavily when platform claims are tied to tangible pipeline output rather than abstract model performance.
How this works
Discover
An automated pipeline searches the web for significant AI healthcare news across clinical, research, regulatory, and industry domains.
Structure
The pipeline turns source material into concise, readable stories with categories, tags, and context that make the feed easier to scan.
Publish
Stories are deduplicated, stored, and published to this site. The pipeline runs automatically to keep coverage current.